Catalyst Wire Dossier Catalyst Wire Dossier

CR6086

EP4 antagonist · Rottapharm Biotech
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CR6086, covering 2021-10-05 to 2021-10-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis [Phase 2]

See pricing